
AVROBIO AVRO
Quartalsbericht 2026-Q1
hinzugefügt 07.05.2026
AVROBIO Kurzfristige Verbindlichkeiten 2011-2026 | AVRO
Kurzfristige Verbindlichkeiten Jährlich AVROBIO
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.67 M | 11.6 M | 40.9 M | 13.1 M | 19.4 M | 16.6 M | 14 M | 10.6 M | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 40.9 M | 9.67 M | 17 M |
Kurzfristige Verbindlichkeiten anderer Aktien in der Pharmaeinzelhändler
| Name | Kurzfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Happiness Biotech Group Limited
HAPP
|
6.4 M | - | 1.35 % | $ 17.8 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
158 M | $ 16.89 | -2.37 % | $ 789 M | ||
|
AgeX Therapeutics
AGE
|
3.56 M | - | -10.17 % | $ 12.2 K | ||
|
Compugen Ltd.
CGEN
|
22.6 M | $ 2.85 | -5.94 % | $ 266 M | ||
|
I-Mab
IMAB
|
576 M | - | - | $ 866 M | ||
|
Coherus BioSciences
CHRS
|
140 M | $ 1.58 | -3.37 % | $ 185 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.62 B | - | - | $ 40.3 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.77 M | - | -1.52 % | $ 24.7 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
36.4 M | $ 7.46 | -4.73 % | $ 204 M | ||
|
Athira Pharma
ATHA
|
47.5 M | - | - | $ 269 M | ||
|
Galera Therapeutics
GRTX
|
645 K | - | -32.59 % | $ 7.61 M | ||
|
Eton Pharmaceuticals
ETON
|
38.5 M | $ 29.73 | -0.77 % | $ 800 M | ||
|
Exelixis
EXEL
|
406 M | $ 50.09 | -1.98 % | $ 13.6 B | ||
|
Fortress Biotech
FBIO
|
49.7 M | $ 2.47 | 7.39 % | $ 68.9 M | ||
|
Forte Biosciences
FBRX
|
20.8 M | $ 22.53 | -5.97 % | $ 292 M | ||
|
Fennec Pharmaceuticals
FENC
|
10.5 M | $ 9.51 | 2.92 % | $ 272 M | ||
|
AbCellera Biologics
ABCL
|
64.3 M | $ 4.03 | -8.52 % | $ 1.2 B | ||
|
Autolus Therapeutics plc
AUTL
|
73.4 M | $ 1.57 | -1.26 % | $ 418 M | ||
|
Институт стволовых клеток человека
ISKJ
|
556 M | - | - | - | ||
|
Checkmate Pharmaceuticals
CMPI
|
9.38 M | - | - | $ 231 M | ||
|
Galectin Therapeutics
GALT
|
8.03 M | $ 2.22 | -5.74 % | $ 142 M | ||
|
Gilead Sciences
GILD
|
11.8 B | $ 129.56 | -1.9 % | $ 161 B | ||
|
Advaxis
ADXS
|
25 M | - | -9.65 % | $ 45.9 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
2.73 M | $ 3.36 | -5.62 % | $ 5.53 M | ||
|
Aeglea BioTherapeutics
AGLE
|
58.7 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
25.2 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
1.61 M | - | 1.93 % | $ 17.4 M | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
9.02 M | $ 0.72 | -1.76 % | $ 32.9 M | ||
|
Akero Therapeutics
AKRO
|
39.8 M | - | - | $ 3.67 B | ||
|
Esperion Therapeutics
ESPR
|
301 M | $ 3.13 | 0.32 % | $ 651 M | ||
|
Aptose Biosciences
APTO
|
9.31 M | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
6.29 M | - | -39.0 % | $ 4.57 M | ||
|
Akouos
AKUS
|
16.8 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
45.3 M | - | -0.23 % | $ 916 M | ||
|
AlloVir
ALVR
|
9.71 M | - | 4.14 % | $ 49.1 M | ||
|
Allakos
ALLK
|
36.6 M | - | - | $ 28.6 M | ||
|
Arcutis Biotherapeutics
ARQT
|
130 M | $ 21.66 | 0.42 % | $ 2.76 B | ||
|
Allena Pharmaceuticals
ALNA
|
15.7 M | - | 3.16 % | $ 1.9 M |